



Updates to the Medi-Cal Rx Provider Manual

September 1, 2023

The updates/additions below have been made to the [Medi-Cal Rx Provider Manual](#) version 10.0.

Updates

Section	Update Description	Effective Date
<i>Section 3.3.3.1 – Paper Remittance Advice Example</i>	<ul style="list-style-type: none">• Updated table description verbiage for “Amount Billed.”• Added <i>Figure 3.3.3.1-3</i> to depict the Amount Billed field populated with the Gross Amount.	September 1, 2023
<i>Section 12.0 – Enteral Nutrition Products</i>	<ul style="list-style-type: none">• Updated language pertaining to eligibility and prior authorization requirements.• Overall section revised and rearranged.	September 1, 2023
<i>Section 12.1 – Noncovered Nutrition Products</i>	<ul style="list-style-type: none">• Removed language to refer to the CDL regarding dietary supplements.	September 1, 2023
<i>Section 12.2 – Covered Products</i>	<ul style="list-style-type: none">• Updated section title.• Updated language to reflect categories of covered products.	September 1, 2023
<i>Section 12.3 – Prescription Requirements</i>	<ul style="list-style-type: none">• Updated section number and title.• Language refined to one section.	September 1, 2023
<i>Section 12.4 – Documentation Requirements</i>	<ul style="list-style-type: none">• Language refined.	September 1, 2023

Section	Update Description	Effective Date
<i>Section 12.5 – Authorization</i>	<ul style="list-style-type: none"> • Updated section title. • Refined language regarding requirements for coverage. • Removed language regarding initial prior authorization documentation. 	September 1, 2023
<i>Section 12.5.1 – Standard Products</i>	<ul style="list-style-type: none"> • Updated section title. • Removed language regarding product specific criteria. 	September 1, 2023
<i>Section 12.5.2 – Specialized Products</i>	<ul style="list-style-type: none"> • Removed language regarding documentation requirements for diabetic, renal, and hepatic products. • Refined language for modular products. 	September 1, 2023
<i>Section 12.5.3 – Elemental and Semi-Elemental Products Criteria</i>	<ul style="list-style-type: none"> • Refined language regarding documentation requirements. 	September 1, 2023
<i>Section 12.5.4 – Metabolic Products Criteria</i>	<ul style="list-style-type: none"> • Updated language regarding member criteria diagnoses. • Added sentence, "A contracted product has been tried and considered and contracted alternatives are otherwise considered to be clinically inappropriate/inadequate to meet the medical needs of the member." • Updated ICD-10-CM Code E71.1. • Removed language regarding authorizations for members 22 years of age and older for ICD-10-CM diagnosis codes listed in the table. 	September 1, 2023
<i>Section 12.5.5 – Specialty Infant Products</i>	<ul style="list-style-type: none"> • Updated section title. • Removed specifications for product types. 	September 1, 2023

Section	Update Description	Effective Date
<i>Section 12.6 – Enteral Nutrition Dispensing Quantity Limitations</i>	<ul style="list-style-type: none"> • Updated section title. • Added language regarding restrictions based on quantity limitations. 	September 1, 2023
<i>Section 12.7 – Billing Requirements</i>	<ul style="list-style-type: none"> • Updated section number. • Updated language regarding coverage of products with an approved prior authorization. 	September 1, 2023
<i>Section 12.8 – Product Interchangeability (NEW!)</i>	<ul style="list-style-type: none"> • Added information about the enteral nutrition coverage policy, substitution, and prescription requirements. 	September 1, 2023
<i>Section 15.7.1 – Emergency Dispensing of 14-Day Supply</i>	<ul style="list-style-type: none"> • Added language specifying the exemption of prior authorizations for Pharmacy Emergency Dispensing. 	September 1, 2023
<i>Section 15.7.3 – Protocol for Overriding Utilization Management (UM) During State of Emergency</i>	<ul style="list-style-type: none"> • Updated section title. 	September 1, 2023
<i>Section 17.0 – COVID-19 Vaccines, OTC Antigen Test Kits, and Therapeutics: Coverage and Reimbursements</i>	<ul style="list-style-type: none"> • Removed language regarding specific vaccines and booster doses for multiple NDCs (Pfizer, Comirnaty, Moderna, Janssen, Pfizer-BioNTech). • Removed tables. • Added additional guidelines for Novavax. • Removed language regarding the use of Janssen per Emergency Use Authorization. • Removed language pertaining to pediatric vaccine coverage. • Overall section revised and renumbered. 	September 1, 2023

Section	Update Description	Effective Date
<i>Section 17.1 – COVID-19 Vaccine Administration Reimbursement</i>	<ul style="list-style-type: none"> Updated section number. Removed language regarding reimbursement for dates of service prior to March 15, 2021. 	September 1, 2023
<i>Section 17.2 – COVID-19 Supplemental Incentive Fee Reimbursement for In-Home Vaccine Administration</i>	<ul style="list-style-type: none"> Updated section number. Removed language regarding reimbursement for dates of service between June 8, 2021 and August 24, 2021. 	September 1, 2023
<i>Section 17.3 – Over-the-Counter (OTC) COVID-19 Antigen Test Kits</i>	<ul style="list-style-type: none"> Updated section number. 	September 1, 2023
<i>Section 17.3.1 – OTC COVID-19 Antigen Test Kits Reimbursement</i>	<ul style="list-style-type: none"> Updated section number. 	September 1, 2023
<i>Section 17.4 – COVID-19 Oral Antiviral Product Coverage</i>	<ul style="list-style-type: none"> Updated section number. 	September 1, 2023
<i>Section 17.4.1 – Paxlovid</i>	<ul style="list-style-type: none"> Updated section number. Removed sentence, “Billable NDCs and maximum quantities are outlined in Table 17.5.2-1 below.” 	September 1, 2023
<i>Section 17.4.2 – Remdesivir (Veklury)</i>	<ul style="list-style-type: none"> Updated section number. Removed tables and language regarding age limitations for antiviral products. 	September 1, 2023
<i>Section 17.4.3 – COVID-19 Oral Antiviral Products Reimbursement</i>	<ul style="list-style-type: none"> Updated section number. 	September 1, 2023

Section	Update Description	Effective Date
<i>Appendix D – NCPDP Reject Codes</i>	<ul style="list-style-type: none"> Removed previous comment for Reject Code 79, "75 percent or more days supply of previous claim has not been utilized for non-controlled products 90 percent or more days supply of previous has not been utilized for controlled products" and replaced with, "See DUR-88 for Refill Too Soon." Added comment for Reject Code 88, "Note: DUR ER – Overuse Precaution will be triggered if at least 75 percent of the days supply has not been used For opioid claims, the trigger occurs if at least 90 percent of days supply has not been used." 	September 1, 2023

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.